Search

everythinglearnresearchcommunity

for

Search:↓

A user experiencing hair loss received three different diagnoses: androgenic alopecia, traction alopecia, and scarring alopecia, and tried treatments like minoxidil and finasteride without success. They are considering dutasteride but were advised to seek anti-inflammatory medication instead.

A 26-year-old with a bald spot is seeking advice for hair regrowth, having no treatment history. Suggestions include starting Minoxidil and finasteride to promote growth and reduce hair loss.

The user is using a treatment of topical minoxidil 7% and finasteride 0.1% twice daily, along with a low-level laser therapy cap, biotin, and collagen supplements, and is seeing good progress on the hairline and temples but not the midscalp. They experienced initial shedding, saw results by month three, and are happy with the progress, though some users express concern about using finasteride at a young age.

A 38-year-old user discusses their experience with hair loss and the impact of comments about their bald spot, despite using treatments like topical finasteride, minoxidil, and tretinoin. The conversation highlights the emotional impact of unsolicited comments on appearance and suggests exploring additional treatments like oral minoxidil and finasteride for further improvement.

User noticed receding/thinning hairline, used topical finasteride/minoxidil and scalp scrubber for 4 months, saw progress.

The conversation is about using DIY deoxyribose topical and botox injections for hair loss. The user is experimenting with these treatments and believes the science is strong.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Topical Dutasteride may halt hair loss and effectively treat androgenic alopecia. Combining low-dose oral Dutasteride with topical application could maximize regrowth and minimize side effects.

User experienced significant hair improvement after 9 months using topical fin/min spray. Noticed positive changes around 3-month mark and chose topical treatment due to fewer side effects.